Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.
Solid Tumor, Adult
DRUG: ABO2011 Injection|DRUG: Toripalimab
Phase I: Incidence and character of DLTs, monotherapy: 21 days after the first dose. Combination therapy: 28 days after the first dose]|Phase I: Incidence of Adverse Event (AE), monotherapy: from informed consent until 28 days after the last administration. Combination therapy: from informed consent until 90 days after the last administration.|Phase I: Incidence of Serious Adverse Event (SAE), monotherapy: from informed consent until 28 days after the last administration. Combination therapy: from informed consent until 90 days after the last administration.]|Phase I: Incidence of patients with clinically significant abnormal laboratory results, monotherapy: from the first dose until 28 days of last administration. Combination therapy: from informed consent until 90 days after the last administration.|Phase II: Objective response rates, Estimated to be from time of informed consent up to 2 years
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.